Sanna Laurila

Helsinki University Hospital

Finland

Research Interests

Explore related searches

Professors in Finland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (9)

Pirjo Nuutila

FINLAND

View details

Lauri Nummenmaa

Professor

FINLAND

View details

Marco Bucci

Karolinska Institutet

SWEDEN

View details

Mueez U-Din

Adjunct Professor

University of Turku

FINLAND

View details

Lihua Sun

University of Turku

FINLAND

View details

Jouni Tuisku

University of Turku

FINLAND

View details

Laura Pekkarinen

University of Turku

FINLAND

View details

Martin Klingenspor

Professor

Ludwig-Maximilians-Universität München

GERMANY

View details

Dariusz Moczulski

Head of Department

Medical University of Lodz

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sanna Laurila

Research Interests

Explore related searches

Contact this professor

Articles (10)

SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study

Insulin-stimulated brain glucose uptake correlates with brain metabolites in severe obesity: A combined neuroimaging study

Secretin modulates appetite via brown adipose tissue-brain axis

Novel effects of the gastrointestinal hormone secretin on cardiac metabolism and renal function

The utilization of positron emission tomography in the evaluation of renal health and disease

Pleiotropic Effects of Secretin: A Potential Drug Candidate in the Treatment of Obesity?

Brown adipose tissue fat-fraction is associated with skeletal muscle adiposity

Secretin activates brown fat and induces satiation

Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

Both sedentary time and physical activity are associated with cardiometabolic health in overweight adults in a 1 month accelerometer measurement

Collaborators (9)

Pirjo Nuutila

Lauri Nummenmaa

Marco Bucci

Mueez U-Din

Lihua Sun

Jouni Tuisku

Laura Pekkarinen

Martin Klingenspor

Dariusz Moczulski

Make your next move.